Benitec Biopharma Inc.
Benitec Biopharma Inc. (BNTC): 1 pipeline candidate · ~125 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
124.8 months
D/E 0.02 · 44% dilution
Lead: Phase 1/Phase 2
1 candidate
N/A
8 buys · 0 sells (180d)
A transparent, data-derived signal for Benitec Biopharma Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$390.6M
Cash
$184.9M
Quarterly Burn
$4.5M
Runway
124.8 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| bb-301 | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
87
Total value held
$370.4M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 11,548,351 | $123.0M |
| janus henderson group plc | 5,752,760 | $61.4M |
| franklin resources inc | 2,378,159 | $25.3M |
| adage capital partners gp, l.l.c. | 2,120,672 | $22.6M |
| vanguard capital management llc | 1,863,112 | $19.8M |
| ra capital management, l.p. | 1,850,000 | $19.7M |
| blackrock, inc. | 1,185,741 | $12.6M |
| infinitum asset management, llc | 923,006 | $9.8M |
| alyeska investment group, l.p. | 750,000 | $8.0M |
| silverarc capital management, llc | 717,725 | $7.6M |
Showing top 10 of 87 institutional holders of Benitec Biopharma Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Benitec Biopharma Inc.'s pipeline?
Benitec Biopharma Inc. (BNTC) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Benitec Biopharma Inc.'s lead drug candidate?
Benitec Biopharma Inc.'s most advanced tracked candidate is bb-301 (Phase 1/Phase 2) for Oculopharyngeal Muscular Dystrophy.
What is Benitec Biopharma Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Benitec Biopharma Inc. has approximately 124.8 months of cash runway.
What is Benitec Biopharma Inc.'s market capitalization?
Benitec Biopharma Inc.'s market capitalization is approximately $390.6M.
Who is the CEO of Benitec Biopharma Inc.?
Dr. Jerel A. Banks M.D., Ph.D. is the chief executive officer of Benitec Biopharma Inc. (BNTC).
Get the full picture on Benitec Biopharma Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.